ACAD News and Press, ACADIA Pharmaceuticals Inc. From 02/25/26

2026-02-25 16:19:16 ET More on Acadia Pharma 44th Annual J.P. Morgan Healthcare Conference ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Op...

- Fourth quarter 2025 GAAP total revenues of $284 million and full year 2025 GAAP total revenues of $1.07 billion, reflecting 9% and 12% year-over-year growth, respectively - Fourth quarter 2025 non-GAAP adjusted total revenues of $298 million and full year 2025 non-GAAP adjusted total re...

HCI Group Inc. (HCI) is expected to report $4.87 for Q4 2025 XPEL Inc. (XPEL) is expected to report $0.43 for Q4 2025 Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report $0.56 for Q4 2025 UMH Properties Inc. (UMH) is expected to report $0.24 for Q4 2025 I...

2026-02-22 08:07:08 ET The last week of February brings another packed stretch of earnings, with a mix of megacap technology leaders, consumer bellwethers, energy producers, financial firms, and high-growth disruptors set to report.... Read the full article on Seeking Alpha For ...

Company to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of...

2026-02-03 10:00:00 ET The following segment was excerpted from Alger Weatherbie Specialized Growth Fund ( AWSAX ) Q4 2025 Commentary ... Read the full article on Seeking Alpha For further details see: Alg...

2026-02-03 08:04:40 ET from RBC Capital issued a price target of $31.00 for ACAD on 2026-02-03 12:47:24. The adjusted price target was set to $31.00. At the time of the announcement, ACAD was trading at $26.13. The overall price target consensus is at $34.71 with high pr...

- Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoption. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Prod...

2026-01-13 16:05:59 ET ACADIA Pharmaceuticals Inc. (ACAD) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:45 PM EST... Read the full article on Seeking Alpha For further details see: ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Hea...

- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID ® and ~$700 million for DAYBUE ® - Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP-204) in Alzheimer’s disease psychosis anticip...